The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research
Open accessAbstract
Breast cancer is a heterogeneous disease with different morphologies, molecular profiles, clinical behaviour and response to therapy. The triple negative is a particular type of breast cancer defined by absence of oestrogen and progesterone receptor expression as well as absence of ERBB2 amplification. It is characterized by its biological aggressiveness, worse prognosis and lack of a therapeutic target in contrast with hormonal receptor positive and ERBB2+ breast cancers. Given these characteristics, triple-negative breast cancer is a challenge in today's clinical practice. A new breast cancer classification emerged recently in the scientific scene based in gene expression profiles. The new subgroups (luminal, ERBB2, normal breast and basal-like) have distinct gene expression patterns and phenotypical characteristics. Triple-negative breast cancer shares phenotypical features with basal-like breast cancer, which is in turn the most aggressive and with worse outcome. Since microarray gene-expression assays are only used in the research setting, clinicians use the triple-negative definition as a surrogate of basal-like breast cancer. The aim of this review, that focuses on triple-negative breast cancer, is to summarize the most relevant knowledge on this particular type of cancer in terms of molecular features, pathogenesis, clinical characteristics, current treatments and the new therapeutic options that include the use of platinum compounds, EGFR antagonists, antiangiogenics and PARP inhibitors. Advances in research are promising and new types of active drugs will become a reality in the near future, making possible a better outcome for this subgroup of breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,067
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Gene-Expression Profiles in Hereditary Breast Cancer
Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 1,733
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
Haffty, B. G., Yang, Q., Reiss, M., Kearney, T., Higgins, S. A., Weidhaas, J., Harris, L., Hait, W., & Toppmeyer, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5664 · Cited by 1,084
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Epidemiology of basal-like breast cancer
Millikan, R. C., Newman, B., Tse, C.-K., Moorman, P. G., Conway, K., Smith, L. V., Labbok, M. H., Geradts, J., Bensen, J. T., Jackson, S., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9632-6 · Cited by 886
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Cancer: Principles and Practice of Oncology
CLAUDINO, W. M., & BIGANZOLI, L. (2007) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2006.00680.x · Cited by 855
Subtypes of Breast Cancer Show Preferential Site of Relapse
Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A. M., Yu, J., Klijn, J. G. M., Foekens, J. A., & Martens, J. W. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5644 · Cited by 813
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Kreike, B., van Kouwenhove, M., Horlings, H., Weigelt, B., Peterse, H., Bartelink, H., & van de Vijver, M. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1771 · Cited by 613
Wooster, R., & Weber, B. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012284 · Cited by 605
BRCA1 dysfunction in sporadic basal-like breast cancer
Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., Savage, K., Gillett, C. E., Schmitt, F. C., Ashworth, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210014 · Cited by 573
An entire functional mammary gland may comprise the progeny from a single cell
Kordon, E. C., & Smith, G. H. (1998) · Development · doi:10.1242/dev.125.10.1921 · Cited by 558
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H., Mok, S. C., & D'Andrea, A. D. (2003) · Nature Medicine · doi:10.1038/nm852 · Cited by 536
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis
Stingl, J., & Caldas, C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2212 · Cited by 470
BRCA1 regulates human mammary stem/progenitor cell fate
Liu, S., Ginestier, C., Charafe-Jauffret, E., Foco, H., Kleer, C. G., Merajver, S. D., Dontu, G., & Wicha, M. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711613105 · Cited by 461
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., Sledge, G. W., & Carey, L. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437
EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer
Hughes-Davies, L., Huntsman, D., Ruas, M., Fuks, F., Bye, J., Chin, S.-F., Milner, J., Brown, L. A., Hsu, F., Gilks, B., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00930-9 · Cited by 421
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
Evidence for a stem cell hierarchy in the adult human breast
Villadsen, R., Fridriksdottir, A. J., Rønnov-Jessen, L., Gudjonsson, T., Rank, F., LaBarge, M. A., Bissell, M. J., & Petersen, O. W. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611114 · Cited by 418
Finn, R. S., Dering, J., Ginther, C., Wilson, C. A., Glaspy, P., Tchekmedyian, N., & Slamon, D. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9463-x · Cited by 409
Huo, D., Ikpatt, F., Khramtsov, A., Dangou, J.-M., Nanda, R., Dignam, J., Zhang, B., Grushko, T., Zhang, C., Oluwasola, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6873 · Cited by 369
Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue
Stingl, J., Eaves, C. J., Zandieh, I., & Emerman, J. T. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010615124301 · Cited by 367
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
Tassone, P., Tagliaferri, P., Perricelli, A., Blotta, S., Quaresima, B., Martelli, M. L., Goel, A., Barbieri, V, Costanzo, F., Boland, C. R., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600859 · Cited by 361
Catteau, A., Harris, W. H., Xu, C.-F., & Solomon, E. (1999) · Oncogene · doi:10.1038/sj.onc.1202509 · Cited by 354
Fulford, L. G., Easton, D. F., Reis‐Filho, J. S., Sofronis, A., Gillett, C. E., Lakhani, S. R., & Hanby, A. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02453.x · Cited by 352
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin, R. L., Nemeth, E., Tran, H., Shvartsman, H. S., Cass, I. A., Narod, S. A., & Karlan, B. Y. (2000) · PubMed · Cited by 324
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
Gusterson, B. A., Warburton, M. J., Mitchell, D., Ellison, M., Neville, A. M., & Rudland, P. S. (1982) · PubMed · Cited by 290
Gusterson, B. A., Ross, D. T., Heath, V. J., & Stein, T. (2005) · Breast Cancer Research · doi:10.1186/bcr1041 · Cited by 282
Nagle, R. B., Böcker, W., Davis, J. R., Heid, H. W., Kaufmann, M., Lucas, D. O., & Jarasch, E. D. (1986) · Journal of Histochemistry & Cytochemistry · doi:10.1177/34.7.2423579 · Cited by 270
VERBEEK, B. S., VROOM, T. M., ADRIAANSEN-SLOT, S. S., OTTENHOFF-KALFF, A. E., GEERTZEMA, J. G. N., HENNIPMAN, A., & RIJKSEN, G. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199612)180:4<383::aid-path686>3.0.co;2-n · Cited by 270
Leong, C.-O., Vidnovic, N., DeYoung, M. P., Sgroi, D., & Ellisen, L. W. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30866 · Cited by 270
O'Shaughnessy, J., Osborne, C., Pippen, J., Yoffe, M., Patt, D., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B., & Bradley, C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3 · Cited by 242
Rice, J. C., Ozcelik, H., Maxeiner, P., Andrulis, I., & Futscher, B. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.9.1761 · Cited by 229
Marsit, C. J., Liu, M., Nelson, H. H., Posner, M., Suzuki, M., & Kelsey, K. T. (2004) · Oncogene · doi:10.1038/sj.onc.1207256 · Cited by 228
Heitz, F., Harter, P., Lueck, H.-J., Fissler-Eckhoff, A., Lorenz-Salehi, F., Scheil-Bertram, S., Traut, A., & Bois, A. D. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.027 · Cited by 224
Lee, T.-H., Avraham, H. K., Jiang, S., & Avraham, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210063200 · Cited by 214
Miles, D., Chan, A., Romieu, G., Dirix, L. Y., Cortes, J., Pivot, X., Tomczak, P., Taran, T., Harbeck, N., & Steger, G. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.lba1011 · Cited by 213
Promoter Hypermethylation of FANCF
Narayan, G., Arias-Pulido, H., Nandula, S. V., Basso, K., Sugirtharaj, D. D., Vargas, H., Mansukhani, M., Villella, J., Meyer, L., Schneider, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0245 · Cited by 190
Familial Invasive Breast Cancers: Worse Outcome Related to BRCA1 Mutations
Stoppa-Lyonnet, D., Ansquer, Y., Dreyfus, H., Gautier, C., Gauthier-Villars, M., Bourstyn, E., Clough, K. B., Magdelénat, H., Pouillart, P., Vincent-Salomon, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4053 · Cited by 174
Wei, M., Grushko, T. A., Dignam, J., Hagos, F., Nanda, R., Sveen, L., Xu, J., Fackenthal, J., Tretiakova, M., Das, S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1277 · Cited by 170
Epithelial Progenitors in the Normal Human Mammary Gland
Stingl, J., Raouf, A., Emerman, J. T., & Eaves, C. J. (2005) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-005-2540-7 · Cited by 164
Carey, L. A., Rugo, H. S., Marcom, P. K., Irvin, W., Ferraro, M., Burrows, E., He, X., Perou, C. M., & Winer, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1009 · Cited by 163
Fayard, B., Bianchi, F., Dey, J. H., Moreno, E., Djaffer, S., Hynes, N. E., & Monard, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4573 · Cited by 142
Diaz, L. K., Cryns, V. L., Symmans, W. F., & Sneige, N. (2007) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181594733 · Cited by 132
Do 'basal-like' breast cancers really exist?
Gusterson, B. A. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2571 · Cited by 125
Beckmann, M., Picard, F., An, H., van Roeyen, C. R. C., Dominik, S., Mosny, D., Schnürch, H.-G., Bender, H., & Niederacher, D. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.234 · Cited by 119
Miller, B. J., Wang, D., Krahe, R., & Wright, F. A. (2003) · The American Journal of Human Genetics · doi:10.1086/378522 · Cited by 106
Collins, N., Wooster, R., & Stratton, M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.526 · Cited by 103
T1N0 Triple Negative Breast Cancer: Risk of Recurrence and Adjuvant Chemotherapy
Kaplan, H. G., Malmgren, J. A., & Atwood, M. K. (2009) · The Breast Journal · doi:10.1111/j.1524-4741.2009.00789.x · Cited by 88
Arya, M., Ahmed, H. U., Silhi, N., Williamson, M. P., & Patel, H. (2007) · Tumor Biology · doi:10.1159/000102979 · Cited by 84
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
Ryan, P. D., Tung, N., Isakoff, S. J., Golshan, M. A., Richardson, A., Corben, A. D., Smith, B. L., Gelman, R. S., Winer, E. P., & Garber, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.551 · Cited by 82
Collins, L. C., Martyniak, A., Kandel, M., et al. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31819c1c93 · Cited by 81
Deciphering the Mammary Epithelial Cell Hierarchy
Stingl, J., Raouf, A., Eirew, P. D., & Eaves, C. J. (2006) · Cell Cycle · doi:10.4161/cc.5.14.2983 · Cited by 79
Haplo-insufficiency of BRCA1 in sporadic breast cancer.
Staff, S. M., Isola, J. J., & Tanner, M. (2003) · PubMed · Cited by 77
Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.
Finn, R., Bengala, C., Ibrahim, N., Strauss, L., Fairchild, J. P., Sy, O., Roche, H. H., Sparano, J. A., & Goldstein, L. J. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-3118 · Cited by 70
FANCF methylation contributes to chemoselectivity in ovarian cancer
Olopade, O. I., & Wei, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00111-9 · Cited by 70
A Growing Network of Cancer-Susceptibility Genes
Venkitaraman, A. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmcibr023150 · Cited by 65
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Gronwald, J., Byrski, T., Huzarski, T., Dent, R. A., Bielicka, V., Zuziak, D., Wiśniowski, R., Lubiński, J., & Narod, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.502 · Cited by 61
Systematic characterisation ofGABRPexpression in sporadic breast cancer and normal breast tissue
Zafrakas, Μ., Chorovicer, M., Klaman, I., Kristiansen, G., Wild, P. J., Heindrichs, U., Knüchel, R., & Dahl, E. (2005) · International Journal of Cancer · doi:10.1002/ijc.21517 · Cited by 41
Yang, Z.-Q., Liu, G., Bollig-Fischer, A. B., Haddad, R., Tarca, A. L., & Ethier, S. P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24518 · Cited by 37
Cited by
Lee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., MacBeath, G., & Yaffe, M. B. (2012) · Cell · doi:10.1016/j.cell.2012.03.031 · Cited by 680
Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
Eroles, P., Bosch, A., Alejandro Pérez-Fidalgo, J., & Lluch, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.005 · Cited by 624
Self-citationPowell, A. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., Telli, M. L., Advani, R. H., Carlson, R. W., Mollick, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033788 · Cited by 531
Liu, H., Patel, M. R., Prescher, J. A., Patsialou, A., Qian, D., Lin, J., Wen, S., Chang, Y.-F., Bachmann, M. H., Shimono, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006732107 · Cited by 465
Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring
McGuire, A., Brown, J. A. L., & Kerin, M. J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9551-7 · Cited by 329
Metadata
- Authors
- Bosch, A., Eroles, P., Zaragoza, R., Viña, J. R., & Lluch, A.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 36
- Issue
- 3
- Pages
- 206-215
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2032007742
- Cited by
- 283
- References
- 86
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.